Cargando…

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study

BACKGROUND: Early [(68)Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity. This study investigates the prognostic value of changes in PET parameters after PRRT. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebbers, Sander C., Heimgartner, Muriël, Barentsz, Maarten W., van Leeuwaarde, Rachel S., van Treijen, Mark J. C., Lam, Marnix M. E. G., Braat, Arthur J. A. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655066/ https://www.ncbi.nlm.nih.gov/pubmed/34881405 http://dx.doi.org/10.1186/s41824-021-00116-z

Ejemplares similares

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2017)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy
por: Ebbers, Sander C., et al.
Publicado: (2022)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models
por: Zhang, Libo, et al.
Publicado: (2017)

Somatostatin Receptor Based Imaging and Radionuclide Therapy
por: Xu, Caiyun, et al.
Publicado: (2015)

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)
por: Ebbers, Sander C., et al.
Publicado: (2020)

Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT
por: Oh, Sowon, et al.
Publicado: (2011)

PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India
por: Sharma, Punit, et al.
Publicado: (2014)

Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
por: Notni, Johannes, et al.
Publicado: (2012)

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
por: Gaffney, Brian, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023)

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
por: Feijtel, Danny, et al.
Publicado: (2021)

Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
por: Roden, Anja C., et al.
Publicado: (2022)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Incidental detection of a tumour on 68-Gallium DOTANOC PET/CT
por: Shah, Hina J., et al.
Publicado: (2014)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

Gallium-68 labelled RGD PET/CT imaging of endothelial activation in COVID-19 patients
por: van Genugten, Evelien A. J., et al.
Publicado: (2023)

Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
por: Kaemmerer, Daniel, et al.
Publicado: (2011)

A Generator-Produced Gallium-68 Radiopharmaceutical for PET Imaging of Myocardial Perfusion
por: Sharma, Vijay, et al.
Publicado: (2014)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial Review
por: Shetty, Deepa, et al.
Publicado: (2018)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

Re-assessing gallium-67 as a therapeutic radionuclide()
por: Othman, Muhamad F. bin, et al.
Publicado: (2017)

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models
por: Ullrich, Martin, et al.
Publicado: (2023)

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT
por: Treglia, Giorgio, et al.
Publicado: (2013)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

SUN-314 Gallium-68 DOTATATE PET/CT for Preoperative Localization of Metastatic Insulinoma
por: Bratman, Russell, et al.
Publicado: (2019)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma
por: Iglseder, Sarah, et al.
Publicado: (2023)

Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE
por: kumar Gupta, Santosh, et al.
Publicado: (2012)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Somatostatin receptor scintigraphy in sarcoidosis
por: Kamphuis, Lieke SJ, et al.
Publicado: (2011)

1(st) World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
por: Padhy, Ajit Kumar
Publicado: (2011)

In Vivo Trafficking of the Anticancer Drug Tris(8-Quinolinolato) Gallium (III) (KP46) by Gallium-68/67 PET/SPECT Imaging
por: Darwesh, Afnan M. F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o3ciqeu3a6ud3ta868tvmestu9